Clinical Trials and Research News Weekly Roundup | Zagazig University Ivermectin VS COVID-19

TrialSite News Weekly Roundup

Video Sponsor: Check out our upcoming conferences. Q1 is a leading provider of high level educational content for the medical device, diagnostic, pharmaceutical, life science, and healthcare industries. At Q1 Productions, we are leaders in developing and delivering executive education in highly regulated industries. Our upcoming Medical Communications & Dissemination of Scientific Information and Pharmaceutical & Biotech Medical Affairs Pre-Launch Strategies Conferences provide medical affairs professionals the chance to participate in discussions in a safe, virtual setting. Join us this September to benchmark with peers, network with industry experts and collaborate on mutual challenges.
Zagazig University Randomized Controlled Ivermectin Study Results Confirms PI Hypothesis: Drug Effective Against COVID-19: A principal investor from Zagazig University, Dr. Waheed Shouman, recently completed a randomized, open label, interventional trial titled “Use of Ivermectin as Prophylactic Option in Asymptomatic Family Close Contact for Patient with COVID-19.” Targeting 340 participants, this study was completed in late Aug...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee